ARTICLE | Clinical News
GSK's losmapimod fails ACS efficacy analysis
October 28, 2015 2:07 AM UTC
GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) said losmapimod ( GW856553) failed to show efficacy against the primary endpoint in an interim analysis of the Phase III LATITUDE-TIMI 60 study to treat acute coronary syndrome (ACS). GSK said the data "did not support investment" in a planned second stage of the study.
The first stage of the placebo-controlled study measured time to first occurrence of cardiovascular death, myocardial infarction, or severe recurrent ischemia in 3,503 ACS patients. ...